By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution

Peritoneal Dialysis International

Volumn 22, Issue 3, 2002, Pages 301-306

  Günal, Ali Ihsan ^a   Celiker, Hüseyin ^a   Akpolat, Nusret ^a   Ünstündag, Bilal ^a   Duman, Soner ^a   Akcicek, Fehmi ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Glucose based dialysis solutions; Neoangiogenesis; Octreotide; Vascular endothelial growth factor

Indexed keywords

DIANEAL; GLUCOSE; OCTREOTIDE; SANDOSTATINE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIALYSATE; DRUG EFFECT; FUNCTION TEST; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HISTOLOGY; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ULTRAFILTRATION; UREA BLOOD LEVEL; VASCULAR DISEASE;

EID: 0036587041     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080202200302     Document Type: Article

References (23)

1. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72:171-6.
2. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18:97-102.
3. Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Hoek FJ, Arisz L. A prospective study of peritoneal transport in CAPD patients. Kidney Int 1994; 45: 1739-44.
4. Mateijsen MAM, van der Wal AC, Hendriks PMEM, Zweers MM, Mulder J, Striujk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19:517-25.
5. Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999; 55:341-56.
6. Krediet RT, Zweers MM, van der Wal AC, Struijk DG. Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000; 20(Suppl 2):S19-25.
7. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996; 271:603-6.
8. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463:260-4.
9. Selgas R, del Peso G, Bajo MA, Castro MA, Molina S, Cirugeda A, et al. Spontaneous VEGF production by cultured peritoneal mesothelial cells from patients on peritoneal dialysis. Perit Dial Int 2000; 20:798-801.
10. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101:1219-24.
11. Grant MB, Wargovich TJ, Ellis EA, Caballero BS, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. Circulation 1994; 89:1511-17.
12. Mentlein R, Eicher O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001; 15:545-50.
13. Cascinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, et al. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 2001; 19:8-12.
14. Linden T, Forsbäck G, Deppisch R, Henle T, Wieslander A. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998; 18:290-3.
15. Nilsson-Thorell CB, Muscalu N, Andrén AH, Kjellstrand PT, Wieslander AP. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1993; 13:208-13.
16. Wieslander AP, Nordin MK, Kjellstrand PT, Boberg UC. Toxicity of peritoneal dialysis fluid on cultured fibroblasts, L-929. Kidney Int 1991; 40:77-9.
17. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW Alterations in non-enzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999; 55:389-99.
18. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
19. Günal AI, Duman S, Sen S, Unsal A, Terzioglu E, Akcicek F, et al. By reducing TGF beta 1, octreotide lessens the peritoneal derangements induced by a high glucose solution. J Nephrol 2001; 14:184-9.
20. Isono M, Cruz MC, Chen S, Hong SW, Ziyadeh FN. Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol 2000; 11:2222-30.
21. Ito T, Yorioka N, Yamamoto M, Kataoka K, Yamakido M. Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells. J Am Soc Nephrol 2000; 11:1969-79.
22. Ha H, Lee HB. Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 2000; 20(Suppl 2):S15-18.
23. Chowers Y, Cahalon L, Lahav M, Schor H, Tal R, Bar-Meir S, et al. Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol 2000; 165:2955-61.